The HIV pandemic has since the 1980’s been responsibly for 35 million deaths across the globe. South Africa bears a particularly heave burden when it comes to the disease with 5.7 million cases as of 2017. A key local issue is the need for affordable anti-retroviral’s for the management of the disease, unfortunately, a lack of local manufacturing has meant that afflicted South Africans often suffer with demand often outweighing supply. Betty’s research involves process development for the anti-HIV drugs tenofovir diisoproxil and tenofovir alenfanamide where she aims to develop more economical routes to these critical pharmaceuticals utilising both traditional batch and flow techniques.

Contact details







Dr Darren Riley